LIN.US

479.76

+0.38%↑

BHP.UK

2,572

+1.74%↑

BHP.US

68.82

+0.89%↑

RIO.US

86.59

+0.99%↑

SCCO

159.24

-0.16%↓

LIN.US

479.76

+0.38%↑

BHP.UK

2,572

+1.74%↑

BHP.US

68.82

+0.89%↑

RIO.US

86.59

+0.99%↑

SCCO

159.24

-0.16%↓

LIN.US

479.76

+0.38%↑

BHP.UK

2,572

+1.74%↑

BHP.US

68.82

+0.89%↑

RIO.US

86.59

+0.99%↑

SCCO

159.24

-0.16%↓

LIN.US

479.76

+0.38%↑

BHP.UK

2,572

+1.74%↑

BHP.US

68.82

+0.89%↑

RIO.US

86.59

+0.99%↑

SCCO

159.24

-0.16%↓

LIN.US

479.76

+0.38%↑

BHP.UK

2,572

+1.74%↑

BHP.US

68.82

+0.89%↑

RIO.US

86.59

+0.99%↑

SCCO

159.24

-0.16%↓

Search

Ternium SA

Open

SectorGrondstoffen

39.07 1.14

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

37.53

Max

39.15

Belangrijke statistieken

By Trading Economics

Inkomsten

392M

122M

Verkoop

-212M

3.7B

K/W

Sectorgemiddelde

17.336

34.302

EPS

0.104

Dividendrendement

7.08

Winstmarge

3.259

Werknemers

33,253

EBITDA

-148M

276M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+4.06% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

7.08%

2.86%

Volgende Winsten

28 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.1B

7.5B

Vorige openingsprijs

37.93

Vorige sluitingsprijs

39.07

Nieuwssentiment

By Acuity

50%

50%

80 / 151 Rangschikking in Basic materials

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Ternium SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mrt 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mrt 2026, 23:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 mrt 2026, 23:59 UTC

Marktinformatie

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mrt 2026, 23:37 UTC

Marktinformatie

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mrt 2026, 22:23 UTC

Marktinformatie

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mrt 2026, 22:18 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mrt 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mrt 2026, 22:08 UTC

Marktinformatie

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mrt 2026, 21:10 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mrt 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie
Winsten
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Ternium SA Prognose

Koersdoel

By TipRanks

4.06% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 39 USD  4.06%

Hoogste 44 USD

Laagste 33 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ternium SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

0

Hold

1

Sell

Technische score

By Trading Central

29.012 / 29.55Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

80 / 151 Rangschikking in Grondstoffen

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ternium SA

Ternium S.A., together with its subsidiaries, manufactures and distributes steel products in Mexico, Southern Region, Brazil, and internationally. It operates through three segments: Steel, Mining, and Usiminas. The Steel segment offers slabs, hot and cold rolled products, coated products, roll formed and tubular products, bars, billets, and other products. Its Mining segment sells iron ore and pellets. The Usiminas segment offers iron ore extraction, steel transformation, and production of capital goods and logistics; and manufactures and sells various products and raw materials, such as flat steel, iron ore, and stamped steel parts for the automotive industry and products for the civil construction and capital goods industry. It also provides medical and social; scrap; renewable energy; and engineering and other services, as well as operates as a distribution company. In addition, the company engages in the exploration, exploitation, and pelletizing of iron ore. Ternium S.A. was founded in 1961 and is based in Luxembourg City, Luxembourg. Ternium S.A. is a subsidiary of Techint Holdings S.à r.l.
help-icon Live chat